Our investigations revealed a MNK-controlled mechanism acting on mTORC2-AKT.
2
Herein, a structure-based virtual screening approach was performed to identify potential MNK inhibitors from natural products.
3
Compound 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clinically.
4
The hit compounds display activity in Mnk biochemical and cellular assays, including acute myeloid leukemia progenitors.
5
MNK-795 would have to be taken only once a day unlike other generic combinations in the market.
6
During the study, subjects took two tablets of MNK-795 every 12 hours.
7
Therefore we suggest that MNK-1 inhibition may present a new target to limit inflammation and remodelling in asthmatic airways.
8
Here, we report the development and application of a mutation-based induced-fit in silico screen to identify novel Mnk inhibitors.
9
We are the first to report that MNK-1 controls chemokine secretion and proliferation in human airway smooth muscle cells.
10
Maris said MNK-795 sales could peak at $200 million by 2017.
11
Collectively, these results suggest that SEL201 has significant antileukemic activity and further underscore the relevance of the MNK pathway in leukemogenesis.
12
This approach will enable further rational structure-based drug design of new Mnk inhibitors and potentially novel ways of therapeutically targeting this kinase.
13
BMO Capital Markets analyst David Maris said MNK-795 sales could peak at $200 million by 2017.
14
Our results show that the activation of p38 and Mnk during MNV1 infection is important for MNV1 replication.
15
The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.
16
In this review the mechanisms of activation of MNK pathways by cytokine receptors are addressed and their roles in diverse cytokine-dependent biological processes are reviewed.